Global biotech company CSL
(ASX:CSL) has reported it net profit after tax (NPAT) attributable to members rose about 35 percent to US$1.1 billion in the half year ending 31 December 2017.
The company also reported stronger revenues, with a lift of 11 per cent to US$4.1 billion. As for its earnings before interest and tax (EBIT), that increased 31 per cent on the prior year to $1.5 billion.
The company declared an interim dividend of 79 US cents per share.
CSL says the strong results reflect the robust demand for their products as well as a patient focused R & D pipeline.
Shares in CSL
(ASX:CSL) are trading 5.5 per cent higher to $149.86.
